Position in MYGN
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$62,184,407
+$22,181,014 QoQ
Shares Held
10,890,440
+22.5% QoQ
Ownership
11.4%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#1
of 196 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 95%
Shared 0%
None 5%
Common Shares in MYGN Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Jun 30, 2026BlackRock, Inc. holds $59,796,815,474 across 40 Diagnostics & Research names. MYGN ranks #27 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TMO |
Thermo Fisher Scientific Inc.
|
30,919,632 | $15,501,866,689 | |
| 2 | DHR |
Danaher Corp /De/
|
55,084,630 | $10,492,520,314 | |
| 3 | IDXX |
Idexx Laboratories Inc /De
|
8,170,178 | $4,301,108,497 | |
| 4 | A |
Agilent Technologies, Inc.
|
25,599,001 | $3,400,315,293 | |
| 5 | ILMN |
Illumina, Inc.
|
19,191,398 | $3,374,423,500 | |
| 6 | WAT |
Waters Corp /De/
|
8,484,939 | $3,182,191,513 | |
| 7 | NTRA |
Natera, Inc.
|
10,914,608 | $2,962,770,335 | |
| 8 | IQV |
Iqvia Holdings Inc.
|
14,549,693 | $2,811,291,673 |
All Filings in MYGN
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $62,184,407 | 10,890,440 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $40,003,393 | 8,889,644 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $94,118,669 | 15,303,850 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $107,578,250 | 14,879,427 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $80,033,686 | 15,072,259 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $137,114,012 | 15,458,176 | Shares | Sole | 2025-05-02 | |
| 2024-12-31 | $218,093,092 | 15,907,593 | Shares | Sole | 2025-02-07 | |
| 2024-09-30 | $422,965,657 | 15,442,339 | Shares | Sole | 2024-11-13 | |
| No filing history on record for this holder in this stock. | ||||||